ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, et al. Oncologist 2022;27:e76-e84.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, et al. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. Oncologist 2022;27:e76-e84.
PMID: 35305096